<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997409</url>
  </required_header>
  <id_info>
    <org_study_id>190851</org_study_id>
    <nct_id>NCT03997409</nct_id>
  </id_info>
  <brief_title>Impact of a Low-Carbohydrate Diet in Pediatric Type 1 Diabetes</brief_title>
  <official_title>Impact of a Low-Carbohydrate Diet on Glycemic Control and Lipids in Pediatric Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dietary carbohydrate consumption is a key factor influencing postprandial glycemia for
      patients with type 1 diabetes mellitus (T1DM). Because post-prandial glucose excursions
      profoundly influence hemoglobin A1c (HbA1c), therapeutic approaches to mitigate post-prandial
      hyperglycemia are of great importance. The quantity and source of carbohydrates affect
      post-prandial glycemia more than any other dietary factor. These findings serve as the
      physiologic basis for a growing interest in carbohydrate-restricted diets in the management
      of T1DM despite American Diabetes Association (ADA) guidelines that discourage restricting
      total carbohydrate intake to less than 130 grams per day. Although case series and
      prospective studies suggest low-carbohydrate diets (LCD) significantly improve HbA1c for
      adults with T1DM, data in the pediatric T1DM population is limited. The investigators will
      conduct a randomized prospective pilot study evaluating glycemic control, lipidemia, and
      quality of life (QOL) in pediatric T1DM patients on a LCD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>HbA1c (%) change from baseline to 12 weeks will be compared between the groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of time spent in the glycemic target of 70 - 140 mg/dL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Obtained from continuous glucose monitor data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of time spent above the glycemic target of 140 mg/dL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Obtained from continuous glucose monitor data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of time spent below the glycemic target of 70 mg/dL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Obtained from continuous glucose monitor data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of time spent in hypoglycemia below 50 mg/dL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Obtained from continuous glucose monitor data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average blood glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in average blood glucose (calculated from continuous glucose monitoring data) from baseline to 12 weeks will be compared between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose standard variation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in the blood glucose standard deviation (obtained from continuous glucose monitor data) from baseline to 12 weeks will be compared between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average total daily dose of insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin pump data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average bolus amount of insulin per day</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin pump data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average basal amount of insulin per day</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin pump data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein particle number</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <description>NMR spectroscopy lipoprofile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High density lipoprotein particle number</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <description>NMR spectroscopy lipoprofile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small low density lipoprotein particle number</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <description>NMR spectroscopy lipoprofile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein size</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <description>NMR spectroscopy lipoprofile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-hydroxybutyrate</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <description>Change in concentration of serum ketones (beta-hydroxybutyrate) from baseline to 12 weeks will be compared between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life Inventory (PedsQL) Diabetes Module</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <description>Quality of Life Measure (score 0 - 100 with higher scores indicating higher QOL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Problem Areas in Diabetes: Teen Version (PAID-T)</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <description>Diabetes distress measure (score 0 - 156 with higher scores indicating increased distress)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Low Carbohydrate Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the LCD intervention will consume 25-35% of total daily intake from carbohydrates, 45-65% from fat and 10-30% from protein.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Carbohydrate Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the SCD intervention will consume 45-65% of total daily caloric intake from carbohydrates, 25-35% from fat and 10-30% from protein.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Dietary Recommendations</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will serve as a control that receives the same number of education sessions as LCD and SCD group to teach general diabetes management but without specific dietary recommendations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary Intervention</intervention_name>
    <description>The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.</description>
    <arm_group_label>Low Carbohydrate Diet</arm_group_label>
    <arm_group_label>Standard Carbohydrate Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with T1DM for at least 12 months

          -  Age 13 to 21 years

          -  Total daily dose of insulin 0.5 to 1.25 units/kg/day

          -  Current use of an insulin pump and CGM

          -  HbA1c between 7% and 10%

          -  Tanner stage 3 to 5 on physical exam

          -  Participant or parent of participant use of smart phone

          -  Able to read and speak English

        Exclusion Criteria:

          -  Any episode of diabetic ketoacidosis (DKA) in the last 12 months

          -  Any episode of severe hypoglycemia (defined as requiring assistance from another
             person, including coma, seizures, or episodes requiring glucagon, IV dextrose or oral
             carbohydrate administered by another person) in the last 12 months

          -  Any prior abnormal fasting lipid panel (LDL &gt; 130)

          -  Additional dietary restrictions

          -  Following a weight-loss or otherwise restrictive diet

          -  Use of medication or supplements other than insulin to control blood glucose

          -  Use of medication or other supplements to lower lipids

          -  Pregnancy or breast feeding

          -  History of hemoglobinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin M Gregory, MD, MSCI</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara H Duffus, MD</last_name>
    <phone>615-875-3269</phone>
    <email>sara.duffus@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justin M Gregory, MD, MSCI</last_name>
    <phone>615-322-7424</phone>
    <email>justin.m.gregory.1@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara H Duffus, MD</last_name>
      <phone>615-875-3269</phone>
      <email>sara.duffus@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Justin M Gregory, MD</last_name>
      <phone>615-322-7427</phone>
      <email>justin.m.gregory.1@vumc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Sara Duffus</investigator_full_name>
    <investigator_title>Clinical Fellow, Division of Pediatric Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Low Carbohydrate Diet</keyword>
  <keyword>Standard Carbohydrate Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

